Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease.

ABSTRACT:

Objective

To determine whether oral quinacrine increases survival in sporadic Creutzfeldt-Jakob disease (sCJD).

Methods

This NIH/National Institute on Aging-funded, double-blinded, placebo-controlled, stratified randomization treatment trial was conducted at the University of California, San Francisco from February 2005 through May 2009 (ClinicalTrials.gov, NCT00183092). Subjects were randomized (50:50) to quinacrine (300 mg daily) or placebo with inpatient evaluations at baseline, and planned for months 2, 6, and 12. Subjects returning for their month-2 visit were offered open-label quinacrine. The primary outcome was survival from randomization to month 2.

Results

Of 425 patients referred, 69 subjects enrolled, 54 subjects were randomized to active drug or placebo,

SUBMITTER: Geschwind MD 

PROVIDER: S-EPMC4211922 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature